Ovine adenovirus vectors mediate efficient gene transfer to skeletal muscle

Gene Therapy

Volumn 7, Issue 17, 2000, Pages 1491-1498

  Loser P ^a   Hillgenberg, M ^a   Arnold, W ^a   Both, G W ^b   Hofmann, C ^a  

^a HepaVec GmbH   (Germany)

^b CSIRO   (Australia)

Author keywords

Human 1 antitrypsin; Ovine adenovirus vectors; Pre existing antibodies; Readministration; Skeletal muscle

Indexed keywords

ALPHA 1 ANTITRYPSIN; VIRUS DNA; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; TISSUE GROWTH; TRANSGENE; VACCINATION; VIRUS GENE; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS RECOMBINANT;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; HUMAN ADENOVIRUS; OVIS;

EID: 0033795469     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301260     Document Type: Article

References (50)

1. Systemic delivery of recombinant proteins by genetically modified myoblasts
2. Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo
3. Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle
4. Long-term expression of erythropoietin in the systemic circulation of mice after intramuscular injection of a plasmid DNA vector
5. An improved plasmid DNA expression vector for direct injection into skeletal muscle
6. Cellular and humoral immune response to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression
7. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector
8. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes
9. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells
10. Persistence in muscle of an adenoviral vector that lacks all viral genes
11. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
12. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
13. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immuno-competent mice
14. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia
15. A differential efficiency of adenovirus-mediated in vivo gene transfer into skeletal muscle cells of different maturity
16. Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants
17. Expression of the primary coxsackie and adenovirus receptor is downregulated during skeletal muscle maturation and limits the efficacy of adenovirus-mediated gene delivery to muscle cells
18. Adenovirus
19. Immune response to adenovirus and adeno-associated virus in humans
20. Characterization of human T cell responses to adenovirus
21. Ovine adenovirus vectors overcome preexisting humoral immunity against human adenovirus in vivo
22. Ovine adenovirus vectors promote efficient gene delivery in vivo
23. Characterisation of Australian ovine adenovirus isolates
24. Sequence of ovine adenovirus 100k hexon assembly, 33k, pVIII and fiber genes: Early region E3 is not in the expected location
25. Nucleotide sequence of ovine adenovirus tripartite leader sequence and homologous of IVa2, DNA polymerase and terminal proteins
26. Unique genome arrangement of an ovine adenovirus: Identification of new proteins and proteinase cleavage sites
27. Identification of transcripts and promoter regions of ovine adenovirus OAV287
28. Ovine adenovirus (OAV287) lacks a virus-associated RNA gene
29. Close phylogenetic relationship between egg drop syndrome virus, bovine adenovirus serotype 7, and ovine adenovirus strain 287
30. Phylogenetic analysis of adenovirus sequences. Proof of the necessity of establishing a third genus in the adenoviridae family
31. Strain related variations in adenovirally mediated transgene expression from mouse hepatocytes in vivo: Comparisons between immunocompetent and immunodeficient inbred strains
32. Adenovirus-mediated gene transfer: Influence of transgene, mouse strain and type of immune response on persistence of transgene expression
33. Immune response to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wildtype and E2a deleted vectors
34. Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice
35. FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer
36. Immunology of gene therapy with adenoviral vectors in mouse skeletal muscle
37. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
38. Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis
39. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs
40. Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle
41. Canine adenovirus vectors: An alternative for adenovirus-mediated gene transfer
42. Adenoviral vector-mediated expression of physiologic levels of human factor VIII in non-human primates
43. Sustained expression of therapeutic levels of human factor VIII in mice
44. Sequential nucleic acid and recombinant adenovirus vaccination induces host-protective immune responses against Taenia ovis infection in sheep
45. Immune response to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
46. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy
47. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
48. Cell lines for growth of sheep viruses
49. HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene
50. Transient immunosuppression with 15-deoxyspergualin prolongs reporter gene expression and reduces humoral immune response after adenoviral gene transfer